RESUMEN
In 2010, a tissue-engineered trachea was transplanted into a 10-year-old child using a decellularized deceased donor trachea repopulated with the recipient's respiratory epithelium and mesenchymal stromal cells. We report the child's clinical progress, tracheal epithelialization and costs over the 4 years. A chronology of events was derived from clinical notes and costs determined using reference costs per procedure. Serial tracheoscopy images, lung function tests and anti-HLA blood samples were compared. Epithelial morphology and T cell, Ki67 and cleaved caspase 3 activity were examined. Computational fluid dynamic simulations determined flow, velocity and airway pressure drops. After the first year following transplantation, the number of interventions fell and the child is currently clinically well and continues in education. Endoscopy demonstrated a complete mucosal lining at 15 months, despite retention of a stent. Histocytology indicates a differentiated respiratory layer and no abnormal immune activity. Computational fluid dynamic analysis demonstrated increased velocity and pressure drops around a distal tracheal narrowing. Cross-sectional area analysis showed restriction of growth within an area of in-stent stenosis. This report demonstrates the long-term viability of a decellularized tissue-engineered trachea within a child. Further research is needed to develop bioengineered pediatric tracheal replacements with lower morbidity, better biomechanics and lower costs.
Asunto(s)
Ingeniería de Tejidos/métodos , Tráquea/trasplante , Niño , HumanosRESUMEN
Laryngeal functional impairment relating to swallowing, vocalisation, and respiration can be life changing and devastating for patients. A tissue engineering approach to regenerating vocal folds would represent a significant advantage over current clinical practice. Porcine hemi-larynx were de-cellularised under negative pressure. The resultant acellular scaffold was seeded with human bone marrow derived mesenchymal stem cells and primary human epithelial cells. Seeded scaffolds were implanted orthotopically into a defect created in the thyroid cartilage in 8 pigs and monitored in vivo for 2 months. In vivo assessments consisted of mucosal brushing and bronchoscopy at 1, 2, 4, and 8 weeks post implantation followed by histological evaluation post termination. The implanted graft had no adverse effect on respiratory function in 6 of the 8 pigs; none of the pigs had problems with swallowing or vocalisation. Six out of the 8 animals survived to the planned termination date; 2 animals were terminated due to mild stenosis and deep tissue abscess formation, respectively. Human epithelial cells from mucosal brushings could only be identified at Weeks 1 and 4. The explanted tissue showed complete epithelialisation of the mucosal surface and the development of rudimentary vocal folds. However, there was no evidence of cartilage remodelling at the relatively early censor point. Single stage partial laryngeal replacement is a safe surgical procedure. Replacement with a tissue engineered laryngeal graft as a single procedure is surgically feasible and results in appropriate mucosal coverage and rudimentary vocal fold development.
Asunto(s)
Deglución , Laringe/metabolismo , Fonación , Trasplante de Células Madre , Células Madre/metabolismo , Ingeniería de Tejidos , Animales , Femenino , Humanos , PorcinosRESUMEN
Human cytomegalovirus (HCMV) remains an important cause of morbidity after allotransplantation, causing a range of direct effects including hepatitis, pneumonitis, enteritis and retinitis. A dominant risk factor for HCMV disease is high level viral replication in blood but it remains unexplained why only a subset of patients develop such diseases. In this detailed study of 25 renal transplant recipients, we show that functional impairment of HCMV specific CD8 T cells in the production of interferon gamma was associated with a 14-fold increased risk of progression to high level replication. The CD8 T-cell impairment persisted during the period of high level replication and was more prominent in patients above 40 years of age (odds ratio = 1.37, p = 0.01) and was also evident in dialysis patients. Threshold levels of functional impairment were associated with an increased risk of future HCMV replication and there was a direct relationship between the functional capacity of HCMV ppUL83 CD8 T cells and HCMV load (R(2)= 0.83). These results help to explain why a subset of seropositive individuals develop HCMV replication and are at risk of end-organ disease and may facilitate the early identification of individuals who would benefit from targeted anti-HCMV therapy after renal transplantation.
Asunto(s)
Linfocitos T CD8-positivos/inmunología , Infecciones por Citomegalovirus/inmunología , Trasplante de Riñón/inmunología , Antivirales/uso terapéutico , Citomegalovirus/genética , Citomegalovirus/fisiología , Infecciones por Citomegalovirus/tratamiento farmacológico , Infecciones por Citomegalovirus/epidemiología , ADN Viral/genética , ADN Viral/aislamiento & purificación , Femenino , Estudios de Seguimiento , Ganciclovir/uso terapéutico , Humanos , Interferón gamma/sangre , Trasplante de Riñón/efectos adversos , Masculino , Reacción en Cadena de la Polimerasa , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/virología , Estudios Prospectivos , Replicación ViralRESUMEN
BACKGROUND/AIMS: Hepatocyte progenitors have frequently been cultured from rodents but reports from human liver are rare. METHODS: Non-parenchymal cell fraction isolated from 19 explant livers (removed at orthotopic liver transplantation for acute or chronic liver disease) and histologically normal human liver was cultured. RESULTS: Proliferating epithelioid colonies were identifiable after 2-3 weeks culture as a very rare event (<1 per million cells plated) expressing mRNAs and protein antigens of mixed hepatocytic/biliary phenotype. Colony survival could be prolonged by transduction of the catalytic sub-unit of telomerase. Hepatocyte growth factor, epidermal growth factor and oncostatin M did not further enhance hepatocytic differentiation. The expression of markers associated with hepatocyte precursor status was investigated by flow cytometry. Cells expressing the stem cell-associated markers CD133 and CD117 were identified at low frequency. The proportion of cells expressing the integrin CD49f was higher in diseased liver than in normal liver, but the proportion expressing the hepatocyte growth factor receptor c-met was lower. Successful enrichment of plated populations for progenitors was not achieved. CONCLUSION: Although there is clear histological evidence of hepatocyte precursors in human explant livers, predictable culture of such cells with differentiation toward mature hepatocyte phenotype remains elusive.
Asunto(s)
Proliferación Celular , Células Madre Hematopoyéticas/citología , Hepatectomía , Hepatopatías/patología , Hepatopatías/cirugía , Hígado/citología , Antígeno AC133 , Antígenos CD/biosíntesis , Biomarcadores , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Separación Celular/clasificación , Separación Celular/métodos , Células Cultivadas , Receptores ErbB/biosíntesis , Citometría de Flujo , Glicoproteínas/biosíntesis , Células Madre Hematopoyéticas/clasificación , Células Madre Hematopoyéticas/patología , Células Madre Hematopoyéticas/fisiología , Hepatocitos/clasificación , Hepatocitos/citología , Hepatocitos/fisiología , Humanos , Integrina alfa6/biosíntesis , Hígado/patología , Hígado/fisiología , Hepatopatías/clasificación , Trasplante de Hígado , Oncostatina M/farmacología , Péptidos , Fenotipo , Proteínas Proto-Oncogénicas c-kit/biosíntesis , Proteínas Proto-Oncogénicas c-met/biosíntesisRESUMEN
We have studied the in vitro actions of the sesquiterpene lactone parthenolide (PTL) on cells isolated from patients with chronic lymphocytic leukemia (CLL). Dye reduction viability assays showed that the median LD(50) for PTL was 6.2 muM (n=78). Fifteen of these isolates were relatively resistant to the conventional agent chlorambucil but retained sensitivity to PTL. Brief exposures to PTL (1-3 h) were sufficient to induce caspase activation and commitment to cell death. Chronic lymphocytic leukemia cells were more sensitive towards PTL than were normal T lymphocytes or CD34(+) haematopoietic progenitor cells. The mechanism of cell killing was via PTL-induced generation of reactive oxygen species, resulting in turn in a proapoptotic Bax conformational change, release of mitochondrial cytochrome c and caspase activation. Parthenolide also decreased nuclear levels of the antiapoptotic transcription factor nuclear factor-kappa B and diminished phosphorylation of its negative regulator IkappaB. Killing of CLL cells by PTL was apparently independent of p53 induction. This is the first report showing the relative selectivity of PTL towards CLL cells. The data here warrant further investigation of this class of natural product as potential therapeutic agents for CLL.
Asunto(s)
Apoptosis/efectos de los fármacos , Lactonas/farmacología , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Sesquiterpenos/farmacología , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Células Madre Hematopoyéticas/efectos de los fármacos , Humanos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , FN-kappa B/efectos de los fármacos , Linfocitos T/efectos de los fármacos , Proteína p53 Supresora de Tumor/efectos de los fármacos , Proteína p53 Supresora de Tumor/metabolismo , Regulación hacia ArribaRESUMEN
Tissue engineered tracheae have been successfully implanted to treat a small number of patients on compassionate grounds. The treatment has not become mainstream due to the time taken to produce the scaffold and the resultant financial costs. We have developed a method for decellularization (DC) based on vacuum technology, which when combined with an enzyme/detergent protocol significantly reduces the time required to create clinically suitable scaffolds. We have applied this technology to prepare porcine tracheal scaffolds and compared the results to scaffolds produced under normal atmospheric pressures. The principal outcome measures were the reduction in time (9 days to prepare the scaffold) followed by a reduction in residual DNA levels (DC no-vac: 137.8±48.82 ng/mg vs. DC vac 36.83±18.45 ng/mg, p<0.05.). Our approach did not impact on the collagen or glycosaminoglycan content or on the biomechanical properties of the scaffolds. We applied the vacuum technology to human tracheae, which, when implanted in vivo showed no significant adverse immunological response. The addition of a vacuum to a conventional decellularization protocol significantly reduces production time, whilst providing a suitable scaffold. This increases clinical utility and lowers production costs. To our knowledge this is the first time that vacuum assisted decellularization has been explored. Copyright © 2015 John Wiley & Sons, Ltd.
Asunto(s)
Ingeniería de Tejidos/métodos , Tráquea/citología , Tráquea/fisiología , Vacio , Animales , Materiales Biocompatibles/farmacología , Fenómenos Biomecánicos , Núcleo Celular/efectos de los fármacos , Núcleo Celular/metabolismo , Colágeno/metabolismo , ADN/metabolismo , Matriz Extracelular/efectos de los fármacos , Matriz Extracelular/metabolismo , Glicosaminoglicanos/metabolismo , Antígenos de Histocompatibilidad Clase I/metabolismo , Humanos , Proyectos Piloto , Sus scrofa , Andamios del Tejido/químicaRESUMEN
INTRODUCTION: Platelet Monocyte Complexes (PMCs) are commonly expressed in coronary artery disease but their pathologic significance in ST elevation myocardial infarction (STEMI) is unclear. This study evaluates the relationship between locally activated PMCs and intracoronary inflammation in stable and unstable coronary disease. MATERIAL AND METHODS: Micro catheter aspirated blood samples of 15 STEMI and 7 stable angina patients are collected from the coronary artery (CA), aorta (AO) and right atrium (RA). Samples are labelled with monoclonal antibodies and prepared for flow cytometry. CD 14 and CD 61 double positive cells are identified as PMC. P-selectin expression is identified by additional CD62P positivity and TF expression by additional CD142 positivity. Plasma TNF-alpha and IL-6 are measured using ELISA and CRP is measured in plasma using a high sensitivity automated microparticle enhanced latex turbidimetric immunoassay. RESULTS: No site-specific difference is seen in overall PMC expression in STEMI or stable angina. Surface P-selectin expression in STEMI [median (IQR)] is significantly higher in CA [35.01 (23.15-56.99)] compared with AO [15.99 (10.3-18.85)] or RA [14.02 (10.42-26.08)] (pâ=â0.003). Intracoronary PMC correlates significantly with intracoronary TNF-alpha (râ=â0.87, pâ=â0.001) and intracoronary IL-6 (râ=â0.76, pâ=â0.03). Bound monocytes within P-selectin positive and tissue factor positive complexes correlate positively with intracoronary TNF-alpha (râ=â0.81, pâ=â0.008 & râ=â0.80, pâ=â0.009 respectively) and IL-6 (râ=â0.54, pâ=â0.16 & râ=â0.71, pâ=â0.05 respectively). No such correlation is observed in the peripheral circulation of STEMI and stable angina patients. CONCLUSION: Inflammation is not attributable to PMC formation per se. However, increased intracoronary P-selectin expression by activated platelets and tissue factor expression by activated monocytes within the complexes are determinants of local intracoronary inflammatory burden in STEMI.
Asunto(s)
Plaquetas/metabolismo , Inflamación/sangre , Monocitos/metabolismo , Infarto del Miocardio/sangre , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Miocardio/patologíaRESUMEN
Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013-2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies.
RESUMEN
Graft-vs.-leukemia (GVL) is postulated to be the principal mechanism responsible for continued remission after allogeneic bone marrow transplantation (BMT). The specific cytotoxic effectors mediating this effect are as yet undefined, but the major histocompatibility complex (MHC)-nonrestricted lysis of tumor cell lines by natural killer (NK) and lymphokine-activated killer (LAK) cells from recipients of allogeneic BMTs has been proposed as an in vitro correlate of GVL. In vitro culture or treatment in vivo with interleukin-2 (IL-2) is associated with enhanced NK cytotoxicity and lysis of NK-resistant targets (LAK cytotoxicity). NK, LAK, and cytotoxic T lymphocytes (CTL) have cytotoxic properties against autologous and allogeneic leukemic targets. These immune effector cells require receptor-ligand interaction for target recognition and adhesion via specific molecules such as integrins, a group of heterodimeric transmembrane glycoproteins. The integrins include the very late activation (VLA) subfamily, which all share the same beta 1 subunit but have distinct chains. VLA-6 (CDw49f) has been identified on NK cells and binds to laminin, a basement membrane protein found on malignant tumor cells but not normal cells. Monoclonal antibodies (mAbs) to laminin have been found to inhibit in vitro cytotoxicity of the tumor cell line K562, suggesting an important role for VLA-6 in this interaction. The specific aim of this study was to investigate the role of VLA-6 in the interactions of the tumor cell lines K562 and Daudi with peripheral blood lymphocytes (PBL) acting as effectors in cell-mediated cytotoxicity from normal volunteers, patients recovering from chemotherapy, and patients recovering from autologous or allogeneic BMT. In over 96% of assays, incubation of effector cells with anti-CDw49f mAbs led to detectable inhibition of NK and LAK cell-mediated cytotoxicity. More notably, the degree of anti-VLA6-induced suppression of LAK activity was significantly greater in the normal donors than in any of the patient groups, despite a significantly lower incidence of expression of VLA-6 on NK cells from controls than from patients. This implies a reduced role for this adhesion molecule in LAK activity following some form of in vivo stimulation. This hypothesis is supported by the observation that addition of exogenous IL-2 to the cultures ameliorated the effect of VLA-6 blockade, although the incidence and level of VLA-6 expression was unchanged by IL-2. In contrast, VLA-6 blocking led to a greater reduction in NK activity of BMT recipients than of normal donors, demonstrating that the VLA-6 adhesion pathway is important in this group of patients. These results indicate that the VLA-6-laminin interaction is important in normal NK-target interaction but may play a less significant role in the innate cytotoxic response post-BMT, perhaps reflecting subtle differences in the subsets of NK cells present in BMT recipients compared with normal donors.
Asunto(s)
Trasplante de Médula Ósea/inmunología , Citotoxicidad Inmunológica , Integrinas/inmunología , Células Asesinas Naturales/inmunología , Leucemia/inmunología , Receptores de Laminina/inmunología , Anticuerpos Monoclonales/farmacología , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Reacción Injerto-Huésped , Humanos , Integrina alfa6beta1 , Células Asesinas Activadas por Linfocinas/inmunología , Laminina/inmunología , Laminina/metabolismo , Leucemia/terapia , Linfocitos/inmunología , Trasplante Autólogo , Trasplante Homólogo , Células Tumorales CultivadasRESUMEN
Wild-type adeno-associated virus (wtAAV) is a helper-dependent human parvovirus which has the ability to integrate into the genome of a wide variety of human cells, including those of the hemopoietic lineages. Recombinant adeno-associated virus (rAAV) is becoming a good candidate for virally mediated gene therapy. rAAV is likely to be a safe vector in clinical gene transfer, as it has never been associated with any disease despite previous studies showing that up to 70% of adults are seropositive for wtAAV. Seroconversion appears to occur early in life. wtAAV is an upper respiratory tract virus that is gut secreted, but little is known about the integration of latent wtAAV in hemopoietic lineages. Unlike retroviruses, which have been the most common vehicles for gene transfer to date, wtAAV appears to have a preferred integration site in the target cell which has been termed AAVS1. Several studies have shown that wtAAV can only integrate into only one of the pair of chromosome 19 in a cell. This may have implications for the use of rAAV in gene transfer because patients with latent virus would be refractory to further infection with rAAV. We used a polymerase chain reaction (PCR) assay to detect the presence of wtAAV in the bone marrow samples from 106 patients who presented at our institution. We were able to detect the presence of integrated virus in 18 whole marrow samples. Subsequently CD34+ and CD3+ cell subsets were sorted from the cryopreserved marrow of three PCR-positive individuals to assess integration of virus in these cell lineages. In all three samples tested, we were unable to detect wtAAV virus in the CD34+ hematological precursor cells, but a detectable level of integrated viral DNA was demonstrated in the CD3+ cell fraction. Our findings therefore suggest that CD34+ cells might remain a good target for rAAV-mediated gene transfer despite previous wtAAV infection.
Asunto(s)
Médula Ósea/microbiología , Dependovirus/crecimiento & desarrollo , Virosis/microbiología , Adolescente , Adulto , Factores de Edad , Antígenos CD34/análisis , Células de la Médula Ósea , Separación Celular , Células Cultivadas , Niño , Preescolar , ADN Viral/análisis , Virus Defectuosos/crecimiento & desarrollo , Técnicas de Transferencia de Gen , Vectores Genéticos , Células Madre Hematopoyéticas/microbiología , Humanos , Lactante , Leucemia/microbiología , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa/métodos , Integración ViralRESUMEN
Pre-clinical studies of allogeneic stem cell transplantation suggest that depletion of naive T cells from donor lymphocytes will reduce the risk of GvHD but preserve immunity to infectious pathogens. In this study, we have established a clinical-grade protocol under good manufacturing practice conditions for purging CD62L(+) naive T cells from steady-state leukapheresis products using the CliniMACS system. The efficacy of immunomagnetic CD62L depletion was assessed by analysis of cell composition and functional immune responses. A median 2.9 log CD62L depletion was achieved with no evidence of CD62L shedding during the procedure and a mean T-cell yield of 47%. CD62L(-) cells comprised an equal mix of CD4(+) and CD8(+) T cells, with elimination of B cells but maintenance of regulatory T cells and natural killer cell populations. CD62L-depleted T cells were predominantly CD45RA(-) and CD45RA(+) effector memory (>90%) and contained the bulk of pentamer-staining antivirus-specific T cells. Functional assessment of CD62L(-) cells revealed the maintenance of antiviral T-cell reactivity and a reduction in the alloreactive immune response compared with unmanipulated cells. Clinical-grade depletion of naive T cells using immunomagnetic CD62L beads from steady-state leukapheresis products is highly efficient and generates cells suitable for adoptive transfer in the context of clinical trials.
Asunto(s)
Traslado Adoptivo/métodos , Linfocitos T CD8-positivos/inmunología , Memoria Inmunológica/inmunología , Separación Inmunomagnética/métodos , Voluntarios Sanos , HumanosRESUMEN
Interleukin-12 (IL-12) is a cytokine that exhibits pleiotropic effects on lymphocytes and natural killer cells and has been shown to have promise for the immunotherapy of cancer. The combination of the immune costimulatory molecule B7.1 and IL-12 has been shown to be synergistic for T cell activation. By transfecting tumor cells with both IL-12 and B7.1 cDNAs, it may be possible to use these modified targets as vaccines. A major obstacle in designing a vector to deliver these genes results from the structure of IL-12. Functional IL-12 is a heterodimer composed of two distinct subunits that are encoded by separate genes on different chromosomes. Production of functional IL-12 requires the coordinated expression of both genes. This presents several problems in vectors, particularly those in which additional genes, either a co-stimulatory gene or a selectable marker, are inserted. Therefore, we have constructed a single cDNA that encodes a single-chain protein, called Flexi-12, which retains all of the biological characteristics of recombinant IL-12 (rIL-12). The monomeric polypeptide Flexi-12 is able to induce the proliferation of phytohemagglutinin (PHA) blasts, induce PHA blasts to secrete interferon-gamma (IFN-gamma) and additionally, by preincubation, enhance the killing of K562 targets by PBLs. These phenomena are in a dose-dependent manner comparable to that seen with rIL-12. We have also shown that tyrosine phosphorylation of the STAT 4 transcription factor, which has been shown to be unique to the IL-12 signaling pathway, occurs with Flexi-12 at levels similar to those seen with rIL-12. We have packaged Flexi-12 into a recombinant adeno-associated virus (AAV) and used this vector to infect acute myeloid leukemic (AML) blasts. Infected AML blasts produced between 2 and 6 ng of IL-12/10(6) cells per ml per 48 hr. These studies also confirm that AAV is an efficient delivery vehicle for cytokines to leukemic cells. Direct analysis of these modified cells acting as tumor vaccines is underway.
Asunto(s)
Dependovirus/genética , Interleucina-12/genética , Interleucina-12/farmacología , Leucemia Mieloide/tratamiento farmacológico , Proteínas Recombinantes de Fusión/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Células COS/metabolismo , División Celular/efectos de los fármacos , ADN Complementario , Proteínas de Unión al ADN/efectos de los fármacos , Proteínas de Unión al ADN/inmunología , Proteínas de Unión al ADN/metabolismo , Humanos , Interferón gamma/metabolismo , Interleucina-12/metabolismo , Células Asesinas Naturales/efectos de los fármacos , Leucemia Mieloide/genética , Datos de Secuencia Molecular , Fosforilación , Fitohemaglutininas/farmacología , Pruebas de Precipitina , Proteínas Recombinantes de Fusión/metabolismo , Proteínas Recombinantes de Fusión/farmacología , Factor de Transcripción STAT4 , Transducción de Señal , Linfocitos T/efectos de los fármacos , Linfocitos T/metabolismo , Transactivadores/efectos de los fármacos , Transactivadores/inmunología , Transactivadores/metabolismoRESUMEN
Lymphocyte activation remains an area of intense interest to immunologists and cell biologists and the dynamics of expression of surface molecules during the process are widely studied. The CD69 C-type lectin is reportedly the earliest activation antigen on lymphocytes and can be detected within hours of mitogenic stimulation. Recently reports have described differential activation dynamics with respect to different antigenic or mitogenic stimuli. This study has investigated the dynamics of CD69 expression over time after mitogenic, allogeneic, cytokine and target cell mediated activation of T-cell and NK cell subsets. It is apparent that the dynamics of CD69 expression differ with respect to the cell type and the method of stimulation. Mitogenic stimulation resulted in the most rapid expression of CD69 on both T- and NK cells while alloantigen stimulation induced a far slower response. Target cell stimulation of NK cells gave paradoxical results in that the CD69 + ve subset increased as a proportion of the total NK cells but did not increase in number. This was due to the selective binding of CD69 - ve NK cells to the target cells and their subsequent loss from the lymphoid gate. We confirmed this by showing that CD69 + ve NK cells do not lyse K562 target cells. This observation demonstrates the caution needed in the analysis of flow cytometric data based solely upon relative proportions of cells within discrete subsets.
Asunto(s)
Antígenos CD/biosíntesis , Antígenos de Diferenciación de Linfocitos T/biosíntesis , Células Asesinas Naturales/metabolismo , Linfocitos T/metabolismo , Complejo CD3/inmunología , Citotoxicidad Inmunológica , Citometría de Flujo/métodos , Humanos , Interleucina-12/farmacología , Isoantígenos/inmunología , Células Asesinas Naturales/efectos de los fármacos , Lectinas Tipo C , Leucemia Eritroblástica Aguda/inmunología , Fitohemaglutininas/farmacología , Estimulación Química , Linfocitos T/efectos de los fármacos , Acetato de Tetradecanoilforbol/farmacología , Factores de Tiempo , Células Tumorales CultivadasRESUMEN
5 Fluorouracil (5 FU), the most effective systemic chemotherapeutic agent in the management of advanced colorectal carcinoma acts by inducing apoptosis. Response rates, approximately 20% is improved by folinic acid. This study investigates similar modulation of 5 FU-induced apoptosis by oxidant quenching. A five-fold reduction of intracellular oxidant levels by antioxidants N-acetylcysteine and vitamin E did not induce apoptosis, it however augmented pro-apoptotic bax protein expression, and apoptotic response to a non-toxic dose of 5 FU in the colorectal cancer cell lines colo 201 and colo 205. This suggests that reduction of intracellular levels of reactive oxygen species enhance susceptibility to 5 FU (apoptotic stimuli) by augmentation of bax expression.
Asunto(s)
Antioxidantes/uso terapéutico , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/genética , Fluorouracilo/uso terapéutico , Proteínas Proto-Oncogénicas c-bcl-2 , Proteínas Proto-Oncogénicas/biosíntesis , Acetilcisteína/farmacología , Antimetabolitos Antineoplásicos/uso terapéutico , Apoptosis , Western Blotting , Interacciones Farmacológicas , Citometría de Flujo , Depuradores de Radicales Libres/farmacología , Humanos , Oxidación-Reducción , Especies Reactivas de Oxígeno , Factores de Tiempo , Células Tumorales Cultivadas , Vitamina E/farmacología , Proteína X Asociada a bcl-2RESUMEN
CTL and antibody responses to HIV-1 p17 and p24 antigens were monitored from 1986-1991, in 4 hemophiliacs. The patients had been infected with HIV-1 between 1980 and 1984. Two patients have remained asymptomatic while two progressed to AIDS in 1990. CTL were boosted by culturing with peptides from p17 aa 86-115, or p24 aa 265-279; and aa 270-373 or PHA. Lysis was measured on autologous or allogeneic targets pulsed with peptides or infected with recombinant vaccinia virus carrying HIV-1 gag or influenza A matrix genes. Antibodies to p17 and p24 were tested by ELISA using peptides and by Western blotting. High levels of CTL activity to p17 and p24 antigens could be generated only with lymphocytes from the two asymptomatic patients between 1986 and 1989, but these responses were absent in 1990 and 1991. Antibodies to p17 peptides disappeared in parallel with CTL activity. Antibodies to some p24 peptides also declined but most patients retained activity to others. In all patients a > or = 3-fold increase in CD8+ cell numbers occurred over time and accompanied the decline of CTL and antibody responses. The loss of CTL and p17 antibodies occurred irrespective of whether patients remained asymptomatic or progressed to AIDS in the intervening two years.
Asunto(s)
Productos del Gen gag/inmunología , Anticuerpos Anti-VIH/sangre , Antígenos VIH/inmunología , Proteína p24 del Núcleo del VIH/inmunología , Infecciones por VIH/inmunología , VIH-1/inmunología , Linfocitos T Citotóxicos/inmunología , Proteínas Virales , Línea Celular Transformada , Epítopos/inmunología , Estudios de Seguimiento , Anticuerpos Anti-VIH/biosíntesis , Infecciones por VIH/complicaciones , Hemofilia A/complicaciones , Humanos , Fragmentos de Péptidos/inmunología , Productos del Gen gag del Virus de la Inmunodeficiencia HumanaRESUMEN
With the development of haematopoietic stem cell (HSC) mobilisation strategies and the associated technical expertise in leukapheresis has come the need for accurate and reproducible enumeration of HSC in the peripheral blood. Enumeration of HSC is not only required for timing of the harvest but is valuable in determining that the minimum number of HSC required for successful engraftment has been collected. In order to establish a minimum number of HSC required, results from multiple institutions performing such transplants need to be assessed. Clearly, to compare results from multiple centres requires confidence in the reproducibility of the assay. We have evaluated an established EQAS method which has already been proven in the external quality assurance of CD4 measurement in clinical samples to assess the inter- and intra-laboratory reproducibility of CD34 measurement. Fifteen laboratories participated in two distributions in which 28 samples were analysed. Standardised methods were not employed, laboratories using their routine methods. Participants reported their results in terms of '% positive of total leukocytes' and 'absolute number of CD34+/microliters'. A wide range of clinical samples was despatched and analysed with CD34 cell content ranging from 0.08-19.31% positive. The coefficients of variance (CV) associated with the estimations of relative proportions and absolute numbers were maximally 100.1 and 136.6%, respectively. This study highlights the need for external quality assurance and standardisation of the methodology of this assay.
Asunto(s)
Antígenos CD34/sangre , Recuento de Células Sanguíneas/métodos , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/inmunología , Trasplante de Células Madre Hematopoyéticas , Humanos , Laboratorios , Leucaféresis , Fenotipo , Garantía de la Calidad de Atención de Salud , Reproducibilidad de los Resultados , Reino UnidoRESUMEN
It is generally agreed that cord blood (CB) transplantation represents an encouraging alternative to bone marrow (BM) transplantation. There are a variety of reasons for this, the two most controversial being (1) whether there is less graft-versus-host disease with CB compared to BM transplantation and (2) whether we can use more HLA mismatches with CB transplantation? If these are true then CB may generate a lower 'immunological response' compared to transplantation with adult cells. Why this may be is unknown, however, recently there has been much work which compared the immunological function of CB and adult monocytes. Here, we highlight the major contributions from 'The Immunological Properties of CB' session at the 2nd EUROCORD workshop which tried to determine why the immunological response in CB may be lower than that of the adult.
Asunto(s)
Sangre Fetal/inmunología , Adulto , Apoptosis/inmunología , Trasplante de Médula Ósea/inmunología , Unión Europea , Femenino , Enfermedad Injerto contra Huésped/inmunología , Enfermedad Injerto contra Huésped/prevención & control , Trasplante de Células Madre Hematopoyéticas , Prueba de Histocompatibilidad , Humanos , Tolerancia Inmunológica , Recién Nacido , Interleucina-1/sangre , Linfocitos/inmunología , EmbarazoRESUMEN
One of the main goals in allogeneic bone marrow transplantation is the abrogation of graft-versus-host disease with the preservation of antileukaemia and antiviral activity. We have established a novel system for the selective removal of alloreactive lymphocytes from donor grafts while retaining an effective allogeneic response to third-party stimulator cells. Initial feasibility studies were done with unrelated HLA-mismatched pairs and then extended into the matched setting. Mononuclear cells from HLA-matched donors were cocultured with irradiated recipient cells prestimulated with cytokines (gamma-IFN and TNF-alpha) in a modified mixed lymphocyte culture (MLC). Alloreactive donor lymphocytes were identified by expression of CD69, an early activation marker and selectively removed by paramagnetic bead sorting. The remaining 'non-alloreactive' lymphocytes were tested in proliferative assays against the original matched recipient and to a third-party donor. A mean depletion of proliferative capacity to 11.5 +/- 9.9% of the original matched recipient response was achieved while the residual third-party response was largely preserved at 77.8 +/- 20.9% which should translate into improved immune reconstitution and preservation of antiviral activity. The non-alloreactive lymphocytes could also possess functional antileukaemia activity. Moreover, the alloreactive cells are easily recoverable in this selective T cell depletion strategy for cryopreservation and ready for immediate access as therapeutic donor lymphocyte infusions in cases of frank relapse post transplant.
Asunto(s)
Separación Celular/métodos , Enfermedad Injerto contra Huésped/prevención & control , Trasplante de Células Madre Hematopoyéticas , Depleción Linfocítica/métodos , Antígenos CD/metabolismo , Antígenos de Diferenciación de Linfocitos T/metabolismo , Ingeniería Biomédica , Prueba de Histocompatibilidad , Humanos , Técnicas In Vitro , Interferón gamma/farmacología , Lectinas Tipo C , Activación de Linfocitos , Prueba de Cultivo Mixto de Linfocitos , Proteínas Recombinantes , Subgrupos de Linfocitos T/inmunología , Trasplante Homólogo , Factor de Necrosis Tumoral alfa/farmacologíaRESUMEN
Autologous bone marrow transplantation was performed in a 48-year-old man with relapsed high grade lymphoma. Two hours after the marrow infusion he developed pulmonary infiltrates and adult respiratory distress syndrome (ARDS). The aetiology of ARDS in this setting is uncertain but probably relates to pulmonary infection and endotoxaemia present at the time of marrow infusion. As the number of transplant procedures increases, particularly in patients with relapsed or resistant disease, this complication may become more common. In the infected patient in whom it is more likely to occur, prevention may be possible by giving anti-endotoxin antiserum prior to marrow infusion.